Biopharma teams don’t lose because they lack ambition. They lose because the calendar is misaligned.
In licensing, partnering, and BD strategy, timing is everything—yet one of the most overlooked levers is sitting in plain sight: packaging. Specificall…
GPT + Rosalind: What OpenAI’s Life Sciences Model Actually Changes in Drug Development
Drug development has always been a game of time, data, and uncertainty. But in the last year, a new variable has entered the equation: foundation models—systems trai…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Biosimilar timelines are won—or lost—before the first tender is even published.
Most teams in biosimilars still operate on a familiar rhythm: track patent expiry dates, wait for the “moment,” then scramble to engage manufacturers once decisions are eff…
Drug patent protection in Europe: the clock starts ticking long before the first pill hits the shelf—and it doesn’t always last as long as companies assume.
If you’re building a pipeline, underwriting a deal, or pricing risk in Europe, you don’t just n…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
Drug discovery timelines are getting longer—not because science is standing still, but because the workflow is. From target identification to protocol design, from literature triage to experimental planning, teams are still spending too much time trans…
Slash drug discovery timelines with GPT-Rosalind Read Post »
The “Patent Expiration Cliff” Is Coming—So Why Are Some Teams Still Waiting for It to Arrive?
In pharma, timing isn’t just strategy—it’s survival.
For commercial market access vendors, the industry’s most predictable event is also the most disruptive: …
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be a moat. A clean path to market. A period of exclusivity that turns R&D risk into predictable cash flow.
But the market has a …
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
The clock is ticking—and “generic” isn’t a single moment. It’s a timeline.
If you’re in pharma—whether you’re a brand-side strategist, a generic manufacturer, or counsel advising on entry—there’s a temptation to treat regulatory exclusivities like a si…
Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…
Generic entry isn’t just a legal milestone—it’s a pricing event.
When a blockbuster drug approaches patent expiry, the real fight often starts before the first generic pill ever hits the market. And the outcome can determine who gets paid, who gets b…
Get new actionable insights and updates from BiotechBlog
